Table 4.

Association between 25(OH)D-associated SNPs in GWAS (Tier 1 SNPs), an additive genetic risk score, and survival among patients with metastatic colorectal cancer

Outcomea	Unadjusted		Multivariableb
	HR or OR (95% CI)	P	HR or OR (95% CI)	P
Overall survival
rsl993116	1.03 (0.91–1.17)	0.64	0.99 (0.87–1.14)	0.94
rs6013897	0.96 (0.83–1.12)	0.64	0.94 (0.80–1.11)	0.47
rsl2785878	1.05 (0.92–1.20)	0.46	1.00 (0.86–1.16)	0.99
rsl1234027	1.05 (0.89–1.23)	0.57	1.05 (0.89–1.25)	0.54
rs2282679	1.07 (0.92–1.24)	0.36	1.06 ((Ш–1.24)	0.42
Genetic risk score	1.03 (0.97–1.08)	0.36	1.01 (0.95–1.07)	0.79
Time to progression
rsl993116	0.91 (0.80–1.04)	0.16	0.89(0.77–1.02)	0.11
rs6013897	0.92 (0.78–1.09)	0.36	0.90 (0.75–1.07)	0.23
rsl2785878	1.11 (0.97–1.28)	0.14	1.09 (0.93–1.27)	0.27
rsl1234027	1.06 (0.90–1.25)	0.47	1.03 (0.87–1.23)	0.73
rs2282679	1.06 (0.91–1.23)	0.47	1.05 (0.89–1.23)	0.56
Genetic risk score	1.01 (0.95–1.07)	0.82	0.99 (0.93–1.05)	0.76
Tumor response
rsl993116	1.05 (0.82–1.35)	0.68	1.04 (0.80–1.35)	0.78
rs6013897	1.04 (0.78–1.39)	0.78	1.09 (0.80–1.50)	0.58
rsl2785878	0.95 (0.73–1.22)	0.68	1.09 (0.82–1.44)	0.56
rsl1234027	0.94 (0.69–1.28)	0.70	0.98 (0.70–1.36)	0.90
rs2282679	1.11 (0.84–1.46)	0.45	1.04 (0.78–1.40)	0.77
Genetic risk score	1.01 (0.91–1.13)	0.83	1.03 (0.92–1.16)	0.57

25(OH)D 25-hydroxyvitamin D₃, CI confidence interval, ECOG Eastern Cooperative Oncology Group, FOLFOX fluorouracil, leucovorin, oxaliplatin, GWAS genome-wide association studies, HR hazard ratio, IFL irinotecan, bolus fluorouracil, leucovorin, IROX irinotecan, oxaliplatin, OR odds ratio, SNP single-nucleotide polymorphism

^aAdditive effect of a risk allele (i.e., associated with lower 25(OH)D levels) on patient outcome

^bAdjusted for age (continuous), sex (female, male), race/ethnicity (white, black, other, unknown/missing), ECOG performance status (0–1,2), number of metastatic sites (continuous), and treatment arm (IFL, FOLFOX, IROX)